Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study
(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin. (2) Methods: A retrospec...
Saved in:
| Main Authors: | Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Güngör, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/11/502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy
by: Adrián Povo-Retana, et al.
Published: (2024-01-01) -
Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report
by: Sameer Rastogi, et al.
Published: (2020-01-01) -
When DNA Repair Backfires – Trabectedin Induces DNA Breaks in Active Genes
by: Vakil Takhaveev, et al.
Published: (2025-04-01) -
Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas
by: Stephen Poitureau, et al.
Published: (2025-08-01) -
Trabectedin – the DNA minor groove binder
by: G. A. Belitsky, et al.
Published: (2015-06-01)